X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS SUN PHARMA DR. DATSONS LABS/
SUN PHARMA
 
P/E (TTM) x -10.9 25.2 - View Chart
P/BV x 0.2 3.7 4.4% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 DR. DATSONS LABS   SUN PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
SUN PHARMA
Mar-17
DR. DATSONS LABS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs126842 14.9%   
Low Rs31572 5.4%   
Sales per share (Unadj.) Rs133.0131.6 101.0%  
Earnings per share (Unadj.) Rs0.232.7 0.5%  
Cash flow per share (Unadj.) Rs6.638.0 17.4%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs128.8152.7 84.3%  
Shares outstanding (eoy) m31.662,399.26 1.3%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.65.4 10.9%   
Avg P/E ratio x516.121.6 2,386.5%  
P/CF ratio (eoy) x11.818.6 63.6%  
Price / Book Value ratio x0.64.6 13.1%  
Dividend payout %010.7 0.0%   
Avg Mkt Cap Rs m2,4771,696,877 0.1%   
No. of employees `000NA17.5 0.0%   
Total wages/salary Rs m5649,023 0.1%   
Avg. sales/employee Rs ThNM18,028.3-  
Avg. wages/employee Rs ThNM2,798.8-  
Avg. net profit/employee Rs ThNM4,479.5-  
INCOME DATA
Net Sales Rs m4,211315,784 1.3%  
Other income Rs m796,232 1.3%   
Total revenues Rs m4,289322,016 1.3%   
Gross profit Rs m569100,893 0.6%  
Depreciation Rs m20412,648 1.6%   
Interest Rs m4303,998 10.8%   
Profit before tax Rs m1390,479 0.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m-299 -1.8%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m612,116 0.1%   
Profit after tax Rs m578,462 0.0%  
Gross profit margin %13.531.9 42.3%  
Effective tax rate %48.013.4 358.7%   
Net profit margin %0.124.8 0.5%  
BALANCE SHEET DATA
Current assets Rs m6,852329,537 2.1%   
Current liabilities Rs m6,711178,870 3.8%   
Net working cap to sales %3.347.7 7.0%  
Current ratio x1.01.8 55.4%  
Inventory Days Days16179 203.6%  
Debtors Days Days31883 382.5%  
Net fixed assets Rs m3,673204,766 1.8%   
Share capital Rs m3172,399 13.2%   
"Free" reserves Rs m3,761363,997 1.0%   
Net worth Rs m4,078366,397 1.1%   
Long term debt Rs m1,67114,361 11.6%   
Total assets Rs m12,633614,102 2.1%  
Interest coverage x1.023.6 4.4%   
Debt to equity ratio x0.40 1,045.5%  
Sales to assets ratio x0.30.5 64.8%   
Return on assets %3.413.4 25.6%  
Return on equity %0.121.4 0.5%  
Return on capital %7.724.8 30.9%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96444,118 2.2%   
Fx outflow Rs m60724,484 2.5%   
Net fx Rs m35719,634 1.8%   
CASH FLOW
From Operations Rs m1,34570,822 1.9%  
From Investments Rs m-2,256-42,216 5.3%  
From Financial Activity Rs m-1,200-22,854 5.2%  
Net Cashflow Rs m-2,1116,107 -34.6%  

Share Holding

Indian Promoters % 4.5 63.7 7.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 5.1 -  
FIIs % 1.4 23.0 5.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 8.3 1,133.7%  
Shareholders   20,807 133,026 15.6%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  BIOCON LTD  J.B.CHEMICALS  

Compare DR. DATSONS LABS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Apollo Micro Systems Ltd. (IPO)

Jan 9, 2018

Should you subscribe to the IPO of Apollo Micro Systems Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 5-YR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS